Medtronic received information via literature regarding evaluation of aortic annulus diameter and prosthetic valve design.All data were collected from multiple centers between february 2006 and february 2009.The study population included 141 patients (predominantly female; mean age 75 years), 72 of which were implanted with medtronic mosaic ultra (serial numbers not provided).Among all patients, 3% in-hospital operative mortality occurred.Based on the available information, none of the deaths were attributed to medtronic product.Among all patients adverse events included: high gradients, moderate regurgitation, patient prosthesis mismatch, re-exploration for bleeding/tamponade, perioperative stroke, and new permanent pacemaker implantation.Multiple manufacturers were noted in the literature; based on the available information a direct correlation could not be made between the observed adverse events and medtronic product.No additional adverse patient effects were reported.
|